Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.

Gynecologic oncology - 1 Jul 2025

Iida Yasushi, Churchman Michael, Hollis Robert L, Taylor Sarah, Bartos Clare, Croy Ian, Gentleman William, Rye Tzyvia, Nirsimloo Rachel, Herrington C Simon, Gourley Charlie, Okamoto Aikou, Thomson John P

Abstract excerpt

OBJECTIVE: Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, however up to 30 % of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy in early-stage disease (FIGO IA-IC1) remains uncertain. This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort. METHODS: We analyzed 85 CCOC cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Lymphocytes, Tumor-Infiltrating

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Progression-Free Survival

Source

Identifiers

PMID: 40435541
DOI: 10.1016/j.ygyno.2025.05.016

Genes

ARID1A
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.PMID 40435541Read ↗

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinomaSemantic proximity Read ↗

Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.Semantic proximity Read ↗

Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.Semantic proximity Read ↗

Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.Semantic proximity Read ↗

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Semantic proximity Read ↗

APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.Semantic proximity Read ↗

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.Semantic proximity Read ↗

A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrationsSemantic proximity Read ↗

Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.Semantic proximity Read ↗

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 studySemantic proximity Read ↗

Translational genomics of ovarian clear cell carcinoma.Semantic proximity Read ↗

DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.